These findings are confirmed in the blood of patients with MYC+ lymphoma treated with enitociclib and elucidate the mechanism of action of P-TEFb targeting by selective CDK9 inhibition for the treatment of patients with NHL with MYC-driven disease. This evidence concerns the gene MYC and non-Hodgkin lymphoma.